RSRC2 Inhibitors
RSRC2 inhibitors, or inhibitors of RNA-binding motif protein 28 (RBM28) splicing regulator 2 (RSRC2), belong to a class of small molecules designed to specifically target the RSRC2 protein. RSRC2 is a crucial player in RNA processing and splicing mechanisms, which are essential for the proper functioning of eukaryotic cells. These inhibitors are designed to modulate the activity of RSRC2 by interfering with its function, primarily in the context of RNA splicing, and have garnered significant attention in the field of molecular biology and pharmacology.
The mechanism of action of RSRC2 inhibitors typically involves binding to the RSRC2 protein, disrupting its normal interactions with RNA molecules, or other protein partners involved in the splicing process. By doing so, these inhibitors can influence the alternative splicing of pre-mRNA, thereby impacting the diversity of mRNA isoforms produced by a cell. This modulation of splicing patterns can have far-reaching consequences on gene expression, as it can lead to the generation of aberrant transcripts or the exclusion of specific exons, ultimately influencing protein diversity and function. RSRC2 inhibitors have become valuable tools for researchers studying RNA splicing and its role in gene regulation, and they hold promise for potential applications in various aspects of molecular biology and cellular research.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib inhibits tyrosine kinases, particularly BCR-ABL, by binding to the ATP-binding site, blocking phosphorylation and downstream signaling. It is used for chronic myeloid leukemia. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a multi-kinase inhibitor that targets Raf kinases and VEGFR, inhibiting angiogenesis and tumor cell proliferation, used in advanced renal cell carcinoma and hepatocellular carcinoma. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is an EGFR tyrosine kinase inhibitor, blocking phosphorylation of EGFR and downstream signaling pathways, used in non-small cell lung cancer. | ||||||
Imiquimod | 99011-02-6 | sc-200385 sc-200385A | 100 mg 500 mg | $67.00 $284.00 | 6 | |
Imiquimod is an immune response modifier that activates Toll-like receptors, leading to the production of cytokines and antiviral responses. Used topically for genital warts and skin cancer. | ||||||
Tamoxifen | 10540-29-1 | sc-208414 | 2.5 g | $272.00 | 18 | |
Tamoxifen is a selective estrogen receptor modulator (SERM) that competitively binds to estrogen receptors, inhibiting estrogen's effects. It is used in breast cancer | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that blocks the degradation of ubiquitinated proteins, leading to apoptosis in cancer cells. It is used in multiple myeloma and mantle cell lymphoma. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $131.00 $651.00 | 7 | |
Everolimus inhibits mTOR, a kinase involved in cell growth and proliferation, leading to reduced protein synthesis. It's used in various cancers and organ transplant rejection. | ||||||
Lenalidomide | 191732-72-6 | sc-218656 sc-218656A sc-218656B | 10 mg 100 mg 1 g | $50.00 $374.00 $2071.00 | 18 | |
Lenalidomide has immunomodulatory properties, altering cytokine production and enhancing the immune system's response to cancer cells. It's used in multiple myeloma and myelodysplastic syndromes. | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $117.00 $423.00 | 11 | |
Vemurafenib is a BRAF inhibitor that blocks the activity of mutated BRAF proteins in melanoma, disrupting cell growth signaling pathways. | ||||||